Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04514549 · ClinicalTrials.gov registry record
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
A clinical trial of Rett Syndrome, sponsored by Rett Syndrome Research Trust.
- Completed
- Registry status
- 21
- Enrollment target
- 1
- Study location
NCT04514549: Completed study of Rett Syndrome, sponsored by Rett Syndrome Research Trust.
NCT04514549 is a study of Rett Syndrome that has completed, run by Rett Syndrome Research Trust. The registered enrollment target is 21 participants, below the 525-participant average among 18 other Rett Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04514549, a study of Rett Syndrome, has completed, sponsored by Rett Syndrome Research Trust.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study of the Emerald device in Rett syndrome patients diagnosed with a confirmed MECP2 mutation. MC10 BioStamp nPoint patches will also be assessed with the goal to develop Rett-specific breathing algorithms
Primary Outcome
Suitability of Emerald technology to assess sleep staging and
Conditions Studied
Interventions
- DEVICE Emerald
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2023-03-01 |
What the finished NCT04514549 record still lists
NCT04514549 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 525-participant average among 18 other Rett Syndrome trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Emerald is the first listed.
NCT04514549 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04514549 about?
NCT04514549 is a clinical study titled "ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME". This is a pilot study of the Emerald device in Rett syndrome patients diagnosed with a confirmed MECP2 mutation. MC10 BioStamp nPoint patches will also be assessed with the goal to develop Rett-specific breathing algorithms
What is the current status of trial NCT04514549?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2020-11-23. Estimated completion is 2023-03-01.
What conditions does trial NCT04514549 study?
This clinical trial studies the following conditions: Rett Syndrome.
What interventions are being tested in trial NCT04514549?
The interventions under investigation include: Emerald (DEVICE).
Who is sponsoring clinical trial NCT04514549?
This trial is sponsored by Rett Syndrome Research Trust, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04514549 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rett Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04514549's enrollment target sits among peer trials
21 13th of 18 higher than 6 of 18 other Rett Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rett Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rett Syndrome Registry
RECRUITING
-
Cognitive Function in Rett Syndrome During Trofinetide Treatment
RECRUITING
-
Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
RECRUITING
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome
RECRUITING · NA
-
The Rett Syndrome Global Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI